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Abstract
Ninety-nine gastric cancer patients initially received levamisole at a daily dose of 150 mg for
three consecutive days before operation. This therapy was repeated fortnightly (3-day administra-
tion followed by 11-day withdrawal period) for more than one month as long as possible and the
survival rate up to 18 months was compared with thas of control patients. The 18 month survival
rate of advanced Stage IV patients was significantly higher in patients receiving levamisole than
that of control patients. The effects of levamisole in cases of advanced cancer have been discussed
in relation to the literature available.
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Ahstract. Ninety-nine gastric cancer patients initially received leva-
misole at a daily dose of 150 mg for three consecutive days before oper-
ation. This therapy was repeated fortnightly (S-day administration
followed by II-day withdrawal period) for more than one month as
long as possible and the survival rate up to 18 months was compared
with thas of control patients. The 18 month survival rate of advanced
Stage IV patients was significantly higher in patients receiving levami-
sole than that of control patients. The effects of levamisole in cases of
advanced cancer have been discussed in relation to the literature avail-
able.
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Immunotherapy has only recently begun to be used as a form of cancer
therapy, nevertheless with the rapid and remarkable progress in immunotherpy
with bacillu~ Calmette-Guerin (BCG), cancer immunotherapy with immuno-
stimulators extracted from organism holds much promise for the future. In our
previous studies, we treated cancer patients with levamisole, (commonly used
as anthelmintic in Europe and the United States) which was shown first by
Renoux and Renoux (I) to have a stimulating effect on immunity and found in
a small number of cases that therapy with levamisole stimulated the depressed
immunity of cancer patiens relatively rapidly (2) and also increased the survival
rate (3).
This paper is concerned with the investigation of the antitumor effects of
levamisole in gastric cancer patients at relatively clearly defined stages of the
disease. This is the first report in which therapy with levamisole has definitely
been shown to increase survival rate of far advanced (Stage IV) gastric cancer
patients.
MATERIALS AND METHODS
Ninety-nine patients with gastric cancer admitted to our Department of Sur-
gery and subjected to operation were studied. The patients were classified into
Stages I to IV according to the advance of gastric cancer (4). Of these 99, 19 were
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in Stage I, 13 in St~ge U,29 in Sta&e III and 38 in Stage IV cancer. The patients
were also classified by the ,resectability of the tumor: curative resection in 57,
noncurative resection in 35 aiId no resection in 7. Control subjects consisted of 220
gastric cancer patients (36 in Stage I, 29 in Stage II, 51 in Stage III, 104 in Stage
IV, Curative resection in 122, noncurative resct'iOri in 62, no resection in 31) ad-
mitted to our Department and subjected to operation between 1971 and 1976. Gas-
tric cancer Stage IV patients of levamisole-treated and control groups consisted
respectively of 7 and 15 in curative resection, 24 and 58 in noncurative resection
and 7 and 31 without resection. None of these control patients were treated with
levamisole or any other known immunostimulator. The age distribution, method
of operation and form of cancer therapy in the control group were similar to those
in the levamisole-treated group.
The standard course of treatment with levamisole consisted of oral administ-
ration of 150 mg daily for 3 consective days starting 3 days before operation and
repeated fortnightly (3-day administration followed by ll-day withdrawal period)
for more than 1 month and as long as possible.
Statistical analysis of the data on postoperative survival was done by applying
the" x2 " test between the levamisole and control groups.
RESULTS
Six-month survival rate. In ooth the levamisole group and the control group,
a decrease in the 6-month survival rate was observed with advancing stages of
cancer, but the survival rate in the levamisole group did not decrease to a larger
extent than that in the control group. Application of the "x2" test, however,
showed no significant difference in the survival rat~ between the 2 groups at any
stage (Table 1, Fig. 1).
Twelve-month survival rate. The 12-month survival rates for the 2 groups
decreased with advancing stages of cancer similar to the 6-month survival rates.
The 12-month survival in Stage I, II and III patients was not significantly higher
in the levamisole group than in the control group, however, in Stage IV, the
survival rate in the levamisole group was 68.8% (11/16) compared to 45.2%
(47/104) in the control group and the difference was highly significant (x2 = 3.08,
0.05<p<0.1) (Table I, Fig. I).
Eighteen-month survival rate. Because of an extremely small number of
patients in Stage I and II, an analysis of the results will await further studies.
However, from the results there was no significant difference in the 18-month
survival rate in Stage III between the levamisole and control groups, the same
may be estimated regarding either Stage I or II patients. As for Stage IV, the
survival rate in the levamisole group was 53.3% (8/15) as compared to a 27.2%
(28/103) in the control group. The difference was statistically highly signif-
icant (x2 =4.22, 0.02<p<0.05), indicating that the trend observed in the
12-month survival rate was amplified. In view of the aoove, levamisole appears
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TABLE 1. SURVIVAL RATES FOR STAGE I-IV GASTRIC CANCER PATIENTS
6-month survival 12-month survival 18-month survival
Stage of
I-< gastric Control Levamiso1e Control Levamiso1e Control Levamiso1eQJ
u cancer X2 test x2 test X? testQ
«l No. % No. % No. % No. % No. 0/0 No. %0
u
-5
x2=0 x2=0
'" I 36/36 100.° 12/12 35/35 100.0 6/6 29/29 100.0 1/1 100.0«l 100.0 p>0.5 100.0 p>0.5 NS0
'-0
>- X2=0.32 x2=0.21c.. II 28/29 96.6 9/9 28/29 96.6 6/6 23/24 95.8 4/4 100.0 NS«l 100.0 p>0.5 100.° °5I-< p> .QJ
-5
0
x2 =0.12 X2=0.64 X2= 1. 10Q:s III 48/51 94.1 24/25 96.0 p>0.5 42/51 82.4 18/20 90.° O. 2<p<0. 5 36/50 72.0 12/14 85. 7§ 0. 2<p<0. 5
....
IV 75/104 72.1 23/26
x2 = 1. 79
45.2 11/16
x2=3.08
27.2 8/15
X2=4.22
89.5 0.1<p<O.2 47/104 68.8 0.05<p<0.1 28/103 53.3 0.02<p<0.05
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to be more effective in cases of advanced cancer (Table 1, Fig. I).
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Fig. 1. Survival curves up to 18 months after operation for gastric cancer.
-, levamisole group; , control group; LMS, levamisole.
DISCUSSION
Since the antitumor effects of levamisole were reported first by Renoux et at.
in C57BL mice with Lewis lung (3LL) tumor (5), much work has been done on
this subject. Symoens (6), summarizing these reports, concluded that levamisole
has no difinite effect on the proliferation or metastasis of primary tumor of trans-
planted animal cancers but prevents relapse if it is administered after the tumor
cells have been reduced by other measures.
With regard to the effects of levamisole on human cancer, there have been
only a few reports of effective cases in lung cancer and breast cancer and there
has yet been no report dealing with its effects on gastric cancer. The Study
Group for Brochogenic Carcinoma under the leadership of Amery (7) treated
patients with bronchogenic carcinoma with levamisole in the same manner as
ours and observed inhibited relapse and prolonged survival. They also found that
the effects of levamisole were more marked in patients whose excised tumors had
been larger in the longest diameter. Rojas et ai. (8) continued a course of therapy
with levamisole consisting of 3 consective daily doses of 150 mg followed by an
II-day withdrawal in a group of patients with inoperable Stage III breast cancer
following radiotherapy. At 24 weeks post-radiotherapy, 50% of the patients
receiving continued courses of levamisole had no relapse of disease while only 9 %
of control patients were free from disease. The results were in good agreement
with the prolonging effect of levamisole on survival in their series of patients.
Debois (9) also studied the effects of levamisole in breast cancer patients who
received either radiotherapy alone or radiotherapy combined with levamisole at a
daily dose of 150 mg, (3-day treatment plus II-day withdrawal) and compared
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the 25-month survival rates of the 2 groups. The observed result that levamisole
was highly effective in cases of advanced Stage IV cancer resembles closely our
findings in gastric cancer patients. Also there have been a report of cases with
satisfactory results by Renoux and Renoux (10) and that of failure by Lichenfeld
et at. (11).
In its human cancer application, some measures for reducing tumor cells are
necessary to obtain satisfactory results with levamisole therapy.
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